Patients with high intracranial burden and symptomatic presentation at diagnosis demonstrated worse PFS and OS to those with lower burden and absence of symptoms (p < 0.05 for each). Conclusions: Her-2 overexpressing breast cancer and brain metastases face significant challenges, p...
9. Because curative therapy is not yet available for advanced breast cancer, clinicians should encourage eligible patients to participate in clinical trials. In the absence of immediately life-threatening disease, this should include the option of phase 2 and even targeted phase 1 trials before all ...
Impressive Objective Response to Nab-Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER-2 Positive Breast Cancer Patient Case Presentation: We report the case of a 76-year-old Caucasian woman with metastatic HER-2 positive ductal infiltrating breast carcinoma treated with a ... MR...
9. Because curative therapy is not yet available for advanced breast cancer, clinicians should encourage eligible patients to participate in clinical trials. In the absence of immediately life-threatening disease, this should include the option of phase2 and even targeted phase1 trials before all sta...
Julie Shares Symptoms She Had Before Ovarian Cancer Diagnosis (VIDEO) 19 of 19 Julie shared her ovarian and breast cancer stories and wants you to share your health stories too. This Video Improved My Health Changed My Life Saved My Life ...
Discovered during a routine checkup, Judy was shocked and frightened to learn she had a malignant lump in her breast. Judy: At first, the experience of being diagnosed with breast cancer was very frightening. I was shocked because I really had no symptoms. I had gone in to have a pap...
[34,141,142]. Although the pathogenic mechanisms of this syndrome are not known, it has been suggested that at least some of its symptoms could be due to pituitary defects[34]. In humans, the HERC2 genomic locus, including multiple partially duplicated paralogs of HERC2[143], corresponds ...
Hercessi (trastuzumab-strf) is the 6th biosimilar to Herceptin to be granted FDA approval and may be used to treat certain types of HER2+ (Human Epidermal Growth Factor Receptor 2-Positive) cancers, specifically:HER2-overexpressing breast cancer HER2-overexpressing gastric or gastroesophageal junction...
Yes, if it's needed for therapy decision-making, like the tumor biology, it's covered. If it's the germline testing for hereditary breast cancer, it's also covered. So we're in a quite fortunate situation that we can get all the information and then also have the drugs reimbursed alth...
Symptoms and signs Breast cancer itself presents with various symptoms, and some individuals may not experience any noticeable signs. Keep an eye out for: • Discovery of a new lump in the breast or underarm, often without pain. • Changes in the size, shape, or appearance of the breast...